China Diabetes Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

China Diabetes Drugs Market Trends and Insights

Rapid rise in diabetes prevalence & earlier disease onset

Prevalence climbed to 15.88% in 2023 and could reach 29.1% by 2050 if current patterns persist.^{[1]Yu-Chang Zhou, “The National and Provincial Prevalence and Non-Fatal Burdens of Diabetes in China from 2005 to 2023 with Projections of Prevalence to 2050,” Military Medical Research, mmrjournal.biomedcentral.com}Urban youth are being diagnosed earlier, extending lifetime demand for medicine and reshaping portfolio priorities toward long-term metabolic control. Beijing, Shanghai, and Tianjin report the highest incidence, yet rural enclaves are closing the gap as lifestyle and screening converge. This epidemiological swing forces firms to widen access beyond tertiary hospitals and design patient-support tools that span decades of therapy. Direct medical expenditure has already hit USD 165.3 billion, sharpening payer focus on drugs that deliver durable HbA1c control at sustainable prices.

Inclusion of more anti-diabetics in NRDL & volume-based procurement

The 2024 NRDL talks cleared 117 diabetes drugs with an 84.6% success rate, cutting median insulin prices by 42.08% and shifting share toward cost-effective brands.^{[2]Jing Yuan, “National Volume-Based Procurement (NVBP) Exclusively for Insulin: Towards Affordable Access in China and Beyond,” BMJ Global Health, gh.bmj.com}Standardized reimbursement compresses margins for premium imports but simultaneously drives volume for listed molecules by reducing patient co-pays. Domestic manufacturers benefit disproportionately; 71% of newly listed agents originated from Chinese firms. For multinationals, survival hinges on differentiating via novel mechanisms or fixed-dose combinations that escape bulk-purchase ceilings.

Surge in GLP-1/tirzepatide launches and domestic biosimilars

Tirzepatide obtained NMPA clearance in May 2024 and entered clinics in January 2025 at CNY 1,758 per box . Semaglutide biosimilar filings from Hangzhou Jiuyuan, Boan Biotech, and others signal a rush to capture demand once patents lapse in 2026. Gan & Lee’s GZR18 reduced HbA1c by up to 2.32%, surpassing semaglutide’s 1.60% in head-to-head data. Competitive pricing and local supply chain heft are poised to redirect scripts toward domestic injectables, intensifying innovation cycles for originators.

Hospital-to-retail prescription outflow under dual-invoice policy

Uniform invoicing rules let physicians transmit electronic scripts to external dispensaries, breaking hospitals’ stranglehold on chronic-care prescriptions. Patients increasingly fill orders at chain pharmacies and online storefronts, prompting drug makers to reinforce retail relationships and invest in last-mile logistics. Provinces such as Guangdong and Zhejiang, where medical ecommerce is mature, are witnessing double-digit prescription migration rates. Manufacturers with omnichannel capability enjoy higher refill adherence and broader reach into self-pay segments supported by commercial insurance.

Margin squeeze from successive NRDL price cuts

Repeated reimbursement rounds are driving a race to the bottom, with some imported agents reporting exit discussions due to unsustainable economics. Companies must localize production or innovate out of commoditization by bundling devices, apps, or combination regimens that justify premiums. Smaller firms lacking scale are prime acquisition targets as consolidation accelerates.

Intensifying safety scrutiny of long-term GLP-1 use

Reports of cholestatic hepatitis and pancreatitis have triggered extensive pharmacovigilance audits. NMPA reviewers now request larger real-world evidence packages and longer follow-up, extending time-to-market. Prescribers likewise temper enthusiasm, reserving powerful dual agonists for patients with lower cardiovascular or hepatic risk.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: Non-insulin Injectables Drive Innovation

Non-insulin injectables account for 31.34% of 2025 revenue yet deliver the fastest 10.12% CAGR, reflecting strong payor acceptance once NRDL listing is secured. Insulin still holds the largest 46.02% slice of the China diabetes drugs market share, but its single-digit volume growth contrasts sharply with double-digit uptake of GLP-1 and dual agonists. Tirzepatide’s CNY 1,758 pricing undercuts earlier GLP-1 agents while showing over 20% weight loss efficacy, positioning it for rapid formulary wins. Oral DPP-4 inhibitors and SGLT-2 agents remain important entry therapies, often combined with GLP-1 injectables in advanced cases. Peptide capacity expansions by WuXi STA and Aurisco enable domestic suppliers to lower fill-finish costs, reinforcing competitiveness. Combination pens that co-formulate basal insulin with GLP-1 analogues are entering trials, promising simplified regimens and extended patent life. Because most new biologic approvals originate locally, domestic firms now own significant leverage during NRDL negotiations. 

Sequential innovation is shifting clinical practice away from glycemic control alone toward holistic metabolic improvement. Many endocrinologists now start overweight patients on GLP-1 injectables earlier, a practice that could widen the China diabetes drugs market size for non-insulin products by an extra USD 2.62 billion through 2031. Meanwhile, insulin makers reposition ultra-rapid and time-in-range advantages to defend share. The pivot places pressure on production lines to flex between human insulin, analogues, and incretin mimetics to balance risk and sustain utilization.

By Diabetes Type: Type 2 Dominance Intensifies

Type 2 therapies generate 92.64% of 2025 sales and are forecast to expand at a 7.78% CAGR. Younger onset and higher obesity rates extend lifetime drug use, meaning even marginal improvements in adherence translate into substantial incremental revenue. Type 1 patients, though fewer, require complex multi-dose daily regimens and continuous glucose monitoring, fostering demand for sensor-integrated insulin delivery systems. Tonghua Dongbao’s CNY 350 million insulin plant upgrade aims to secure domestic supply for both groups, hedging against import disruptions. 

Polypharmacy is common: peripheral neuropathy sufferers consume an average of 4.7 active agents versus 3.77 for uncomplicated patients.Add-on antiplatelet and lipid-lowering drugs often come from the same manufacturers, giving them cross-selling advantages. As complication management rises in profile, companies that bundle cardiometabolic solutions around GLP-1 anchors will broaden their footprint within the China diabetes drugs market. Population-scale remote monitoring pilots in Shanghai suggest HbA1c can be trimmed 0.45% when tele-coaching is offered, improving outcomes for both Type 2 and insulin-dependent cohorts.

By Drug Origin: Biosimilar Momentum Builds

Branded drugs still command 71.95% of spending, yet their volume edge is eroding as biosimilar pipelines mature. The segment holding the largest China diabetes drugs market size is forecast to cede 8-10 percentage points to generics by 2031, especially after semaglutide patents expire. Hangzhou Jiuyuan’s first-to-file semaglutide biosimilar and Boan’s dulaglutide copycat highlight aggressive timelines. Gan & Lee’s GZR18 Phase III win over Ozempic catalyzed investor confidence, and the drug is now positioned for NRDL entry in the 2026 cycle. 

Pricing pressure accelerates brand erosion; median discounts for biosimilar insulins sit at 35%, while GLP-1 copies are expected to launch 20–30% below innovator tags. To defend value, originators emphasize device convenience (auto-retracting needles, smaller volumes), real-world cardiovascular data, and potential obesity co-indications. Domestic contenders exploit short supply chains to guarantee stock during NRDL rollouts, securing prescriber trust and patient loyalty. Over time, biosimilar penetration will widen formulary breadth but compress the revenue curve, compelling the China diabetes drugs industry to pivot toward first-in-class assets.

By Distribution Channel: Digital Transformation Accelerates

Hospital pharmacies accounted for 63.92% of 2025 turnover, yet the dual-invoice system and electronic prescription law are enabling retail and online sectors to grow at 9.21% CAGR. In pilot provinces, up to 40% of repeat scripts for GLP-1 analogues are now filled through e-pharmacy platforms that deliver next-day nationwide. Chain pharmacies strengthen their bargaining power by integrating telehealth booths, allowing onsite video consults that convert immediately into pharmacy sales. 

Online traffic spikes when new drugs launch but remain excluded from public insurance; self-pay patients often discover products through social media, then purchase via cross-border channels until domestic supply stabilizes. Commercial insurers seize the gap by adding high-profile obesity-adjacent drugs to rider packages, fueling retail volume. For manufacturers, omnichannel success requires coordinated sample distribution, KOL livestreams, and AI-driven adherence reminders. As these elements synchronize, the China diabetes drugs market size derived from non-hospital channels could double from today’s USD 4.15 billion baseline by 2031.

Geography Analysis

Tier-1 municipalities—Beijing, Shanghai, and Tianjin—concentrate one-quarter of national spending, driven by higher disposable income and early adoption of injectables. Provincial bulk procurement equalizes list prices, but hospital formularies in wealthier regions still prioritize novel agents, lifting penetration rates. The eastern seaboard’s digital maturity fosters heavy use of internet hospitals, where up to 60% of follow-up insulin titrations occur virtually. Central and western provinces lag in endocrinologist density, translating into slower uptake of GLP-1 drugs; however, improved 4G coverage and lower device prices are narrowing the gap. 

Manufacturing hubs in Jiangsu, Shanghai, and Guangdong give local firms logistical advantages, including reduced cold-chain transit times. Eli Lilly’s USD 212 million Suzhou upgrade and Sanofi’s EUR 1 billion Beijing insulin plant reflect a strategic pivot to “in-China-for-China” production that hedges against geopolitical shocks. API bottlenecks in inland Sichuan briefly constrained peptide yields in 2024, highlighting the need for multi-site redundancy. 

Reimbursement pilots differ by region: Zhejiang tests outcome-based contracts that withhold 5% of payment until HbA1c goals are met, whereas Hainan’s Free Trade Port permits accelerated importation of unapproved foreign drugs under medical tourism schemes. These heterogeneities compel marketers to segment launch strategies by province, tailoring educational outreach to local prescriber norms.

Regulatory Landscape

China diabetes drug approvals and lifecycle oversight are handled by the National Medical Products Administration (NMPA), while pricing and access are influenced by the National Healthcare Security Administration (NHSA) through NRDL negotiations and volume-based procurement. The Implementing Regulations of the Drug Administration Law (2026 revisions) were issued on Jan 27, 2026 and took effect May 15, 2026, which reinforces special regulatory pathways (priority review, conditional approval, breakthrough therapy) that matter for first-in-class incretins and longer-acting insulins.

Market access increasingly centers on reimbursement and evidence. In 2026, NHSA advanced a dual-track catalog approach, combining the Basic NRDL with a Commercial Health Insurance Innovative Drug Catalog, and published preliminary results during the year, creating an added route for higher-cost innovative therapies outside standard NRDL price discipline. NMPA also operationalized faster clinical development tools, including a 30-day clinical trial application (IND) mechanism for eligible innovative drugs, and tightened expectations for real-world evidence and pharmacovigilance, which aligns with the heightened safety scrutiny for long-term GLP-1 use noted in the market context.

Value Chain Analysis

The China diabetes drugs value chain runs from discovery and clinical development, to regulatory filing, API and peptide synthesis (for GLP-1 and other injectables), and then drug product manufacturing and fill-finish, including devices for pen injectors. After cold-chain and national distribution, volumes reach patients through hospital pharmacies, retail chains, and online/O2O platforms supported by e-prescriptions. NHSA reimbursement placement through NRDL and related catalog pathways remains the main commercialization gate, with procurement and tendering translating listing status into volume shifts.

Manufacturing localization is a key lever for cost, supply assurance, and tender competitiveness, especially for injectable peptides and delivery devices. Eli Lilly’s USD 3 billion China investment plan is tied to local manufacturing, including oral solid dosage capabilities in Beijing and expansion in Suzhou. Novo Nordisk disclosed an expansion of its Tianjin production base with a CNY 200 million investment in June 2026. These moves reinforce in-China production footprints, reduce lead times for chronic therapies, and support scale-up for newer modalities such as GLP-1 and combination products as procurement and reimbursement compress unit prices.

Market Opportunities and Future Outlook

Differentiation opportunities are growing for therapies and services that can hold up under NRDL price pressure, especially in next-generation injectables and fixed-dose combinations that simplify regimens and improve adherence. The 2026 NHSA dual-track approach, pairing the Basic NRDL with a Commercial Health Insurance Innovative Drug Catalog, adds a pathway where commercial reimbursement can absorb part of the affordability burden for higher-cost innovations. This structure creates more room for differentiated GLP-1 and combination products, while broader NRDL negotiations continue to set benchmark pricing.

Supply-side localization and first-launch strategies also open specific execution areas. In June 2026, Novo Nordisk used China for the global first commercial launch of Kyinsu (insulin icodec/semaglutide), pointing to China as an early commercialization venue for novel combination therapies rather than a follow-on market. Announced manufacturing investments, including Eli Lilly’s USD 3 billion plan and Novo Nordisk’s CNY 200 million Tianjin expansion, support faster local availability and strengthen resilience against injectable-grade peptide bottlenecks highlighted in the report context. For domestic players, advancing weekly basal insulin candidates and semaglutide biosimilar programs aligns with the observed shift from insulin dominance toward newer injectables, and it strengthens position in province-level tenders where localized supply and price terms drive outcomes.